Common use of Convertible Senior Note due 2027 Clause in Contracts

Convertible Senior Note due 2027. This Note is one of a duly authorized issue of notes of Cytokinetics, Incorporated, a Delaware corporation (the “Company”), designated as its 3.50% Convertible Senior Notes due 2027 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of July 6, 2022 (as the same may be amended from time to time, the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. Capitalized terms used in this Note without definition have the respective meanings ascribed to them in the Indenture. The Indenture sets forth the rights and obligations of the Company, the Trustee and the Holders and the terms of the Notes. Notwithstanding anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control.

Convertible Senior Note due 2027. This Note is one of a duly authorized issue of notes of CytokineticsNextGen Healthcare, IncorporatedInc., a Delaware corporation (the “Company”), designated as its 3.503.75% Convertible Senior Notes due 2027 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of July 6November 1, 2022 (as the same may be amended from time to time, the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. Capitalized terms used in this Note without definition have the respective meanings ascribed to them in the Indenture. The Indenture sets forth the rights and obligations of the Company, the Trustee and the Holders and the terms of the Notes. Notwithstanding anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control.

Convertible Senior Note due 2027. This Note is one of a duly authorized issue of notes of Cytokinetics, IncorporatedFarfetch Limited, a Delaware corporation Cayman Islands exempted company with limited liability (the “Company”), designated as its 3.503.75% Convertible Senior Notes due 2027 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of July 6April 30, 2022 2020 (as the same may be amended from time to time, the “Indenture”), between the Company and U.S. Bank Trust CompanyWilmington Trust, National Association, as trustee. Capitalized terms used in this Note without definition have the respective meanings ascribed to them in the Indenture. The Indenture sets forth the rights and obligations of the Company, the Trustee and the Holders and the terms of the Notes. Notwithstanding anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control.

Convertible Senior Note due 2027. This Note is one of a duly authorized issue of notes of CytokineticsBeyond Meat, IncorporatedInc., a Delaware corporation (the “Company”), designated as its 3.500% Convertible Senior Notes due 2027 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of July 6March 5, 2022 2021 (as the same may be amended from time to time, the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. Capitalized terms used in this Note without definition have the respective meanings ascribed to them in the Indenture. The Indenture sets forth the rights and obligations of the Company, the Trustee and the Holders and the terms of the Notes. Notwithstanding anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control.

Convertible Senior Note due 2027. This Note is one of a duly authorized issue of notes of CytokineticsDesktop Metal, IncorporatedInc., a Delaware corporation (the “Company”), designated as its 3.506.0% Convertible Senior Notes due 2027 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of July 6May 13, 2022 (as the same may be amended from time to time, the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. Capitalized terms used in this Note without definition have the respective meanings ascribed to them in the Indenture. The Indenture sets forth the rights and obligations of the Company, the Trustee and the Holders and the terms of the Notes. Notwithstanding anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control.

Convertible Senior Note due 2027. This Note is one of a duly authorized issue of notes of CytokineticsZogenix, IncorporatedInc., a Delaware corporation (the “Company”), designated as its 3.502.75% Convertible Senior Notes due 2027 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of July 6September 28, 2022 2020 (as the same may be amended from time to time, the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. Capitalized terms used in this Note without definition have the respective meanings ascribed to them in the Indenture. The Indenture sets forth the rights and obligations of the Company, the Trustee and the Holders and the terms of the Notes. Notwithstanding anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control.